⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 25, 2013BloodOpen Access

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

View Full Paper

Ask AI

Bookmark

Share

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

A 2013 study studied this question.

synapsesocial.com/papers/6a80c1b46170ff5bc645d766 https://doi.org/10.1182/blood-2013-03-490003

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

1Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 20082011 · 216 citations
2Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy2012 · 303 citations
3Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib2011 · 432 citations